Karyopharm Therapeutics Inc. (KPTIQ) stock
Price, market cap and P/E appear here once daily prices are connected.
Earnings
Karyopharm Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Karyopharm Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 2, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026before the open | $33.40M | -11.9% | -$2.32 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 14, 2026before the open | $35.10M | +17.0% | -$1.24 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 12, 2026before the open | $34.10M | +13.7% | -$5.71 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 3, 2025before the open | $44.00M | +13.4% | -$3.82 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 11, 2025before the open | $37.90M | -11.4% | -$4.32 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025after the close | $30.00M | -9.4% | -$2.77 | Release |
| Q4 FY2024ended Dec 31, 2024 | Jan 13, 2025before the open | $30.00M | -11.0% | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 5, 2024before the open | $38.80M | +7.8% | -$0.26 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | $42.80M | +13.8% | -$0.20 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024before the open | $33.10M | -14.5% | -$0.32 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 29, 2024before the open | $33.70M | -1.5% | -$0.36 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023before the open | $36.00M | -0.3% | -$0.30 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 2, 2023before the open | $37.60M | -5.3% | -$0.29 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023before the open | $38.70M | -18.9% | -$0.30 | Release |
| Q4 FY2022ended Dec 31, 2022 | Jan 9, 2023before the open | $34.20M | -72.9% | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022after the close | $36.10M | -4.2% | -$0.45 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | $39.70M | – | -$0.62 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022before the open | $47.70M | – | -$0.53 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 8, 2022before the open | $126.27M | – | $0.46 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 3, 2021before the open | $37.69M | – | -$0.69 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 3, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 11, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 2, 2020after the close | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Jul 14, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Karyopharm Therapeutics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total revenue | FY2026 | $130.00M – $150.00M | $130.00M – $150.00M | Raised | Aug 13, 2026 |
| Total revenue | FY2026 | $130.00M – $150.00M | – | New | Feb 12, 2026 |
| R&D and selling, general and administrative (SG&A) expenses | FY2026 | $230.00M – $245.00M | $230.00M – $245.00M | Reaffirmed | Aug 13, 2026 |
| R&D and selling, general and administrative (SG&A) expenses | FY2026 | $230.00M – $245.00M | – | New | Feb 12, 2026 |
Guidance history
Every forecast Karyopharm Therapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 13, 2026 | R&D and selling, general and administrative (SG&A) expenses | FY2026 | $230.00M – $245.00M | Reaffirmed |
| Aug 13, 2026 | Total revenue | FY2026 | $130.00M – $150.00M | Raised |
| Aug 13, 2026 | U.S. XPOVIO net product revenue | FY2026 | $115.00M – $130.00M | Lowered |
| May 14, 2026 | R&D and selling, general and administrative (SG&A) expenses | FY2026 | $230.00M – $245.00M | New |
| May 14, 2026 | Total revenue | FY2026 | $130.00M – $150.00M | New |
| May 14, 2026 | U.S. XPOVIO net product revenue | FY2026 | $115.00M – $130.00M | Lowered |
| Feb 12, 2026 | R&D and selling, general and administrative (SG&A) expenses | FY2026 | $230.00M – $245.00M | New |
| Feb 12, 2026 | Total revenue | FY2026 | $130.00M – $150.00M | New |
| Feb 12, 2026 | U.S. XPOVIO net product revenue | FY2026 | $115.00M – $130.00M | Lowered |
| Nov 3, 2025 | U.S. XPOVIO net product revenue | FY2025 | $110.00M – $120.00M | Lowered |
| Nov 3, 2025 | R&D and selling, general and administrative (SG&A) expenses | FY2025 | $235.00M – $245.00M | Raised |
| Nov 3, 2025 | Total revenue | FY2025 | $140.00M – $155.00M | Raised |
| Aug 11, 2025 | R&D and selling, general and administrative (SG&A) expenses | FY2025 | $240.00M – $250.00M | Lowered |
| Aug 11, 2025 | Total revenue | FY2025 | $140.00M – $155.00M | Raised |
| Aug 11, 2025 | U.S. XPOVIO net product revenue | FY2025 | $110.00M – $120.00M | Lowered |
| May 12, 2025 | R&D and selling, general and administrative (SG&A) expenses | FY2025 | $240.00M – $255.00M | New |
| May 12, 2025 | Total revenue | FY2025 | $140.00M – $155.00M | New |
| May 12, 2025 | U.S. XPOVIO net product revenue | FY2025 | $115.00M – $130.00M | Lowered |
| Nov 5, 2024 | U.S. XPOVIO net product revenue | FY2024 | $110.00M – $115.00M | Lowered |
| Nov 5, 2024 | R&D and selling, general and administrative (SG&A) expenses | FY2024 | $255.00M – $265.00M | Raised |
| Nov 5, 2024 | Total revenue | FY2024 | $145.00M – $155.00M | Raised |
| Aug 6, 2024 | R&D and selling, general and administrative (SG&A) expenses | FY2024 | $250.00M – $265.00M | Lowered |
| Aug 6, 2024 | Total revenue | FY2024 | $145.00M – $160.00M | Raised |
| Aug 6, 2024 | U.S. XPOVIO net product revenue | FY2024 | $105.00M – $120.00M | Lowered |
| May 8, 2024 | R&D and SG&A expenses | FY2024 | $260.00M – $280.00M | Reaffirmed |
| May 8, 2024 | Total revenue | FY2024 | $140.00M – $160.00M | Raised |
| May 8, 2024 | U.S. XPOVIO net product revenue | FY2024 | $100.00M – $120.00M | Lowered |
| Feb 29, 2024 | R&D and SG&A expenses | FY2024 | $260.00M – $280.00M | New |
| Feb 29, 2024 | Total revenue | FY2024 | $140.00M – $160.00M | New |
| Feb 29, 2024 | U.S. XPOVIO net product revenue | FY2024 | $100.00M – $120.00M | Lowered |
| Nov 2, 2023 | U.S. XPOVIO net product revenue | FY2023 | $110.00M – $125.00M | Reaffirmed |
| Nov 2, 2023 | Non-GAAP R&D and SG&A expenses | FY2023 | $240.00M – $255.00M | Reaffirmed |
| Nov 2, 2023 | Total revenue | FY2023 | $145.00M – $160.00M | Raised |
| Aug 2, 2023 | Non-GAAP R&D and SG&A expenses | FY2023 | $240.00M – $255.00M | Lowered |
| Aug 2, 2023 | Total revenue | FY2023 | $145.00M – $160.00M | Reaffirmed |
| Aug 2, 2023 | U.S. XPOVIO net product revenue | FY2023 | $110.00M – $125.00M | Lowered |
| May 4, 2023 | U.S. XPOVIO net product revenue | FY2023 | $110.00M – $125.00M | New |
| May 4, 2023 | Non-GAAP R&D and SG&A expenses | FY2023 | $245.00M – $260.00M | New |
| May 4, 2023 | Total revenue | FY2023 | $145.00M – $160.00M | New |
| Nov 3, 2022 | XPOVIO net product revenue | FY2022 | $120.00M – $130.00M | New |
| Nov 3, 2022 | Non-GAAP R&D and Selling, general and administrative (SG&A) expenses, excluding stock-based compensation expense | FY2022 | $250.00M – $265.00M | Reaffirmed |
| Nov 3, 2022 | Total revenue | FY2022 | $155.00M – $165.00M | Raised |
| Aug 4, 2022 | Non-GAAP R&D and Selling, general and administrative (SG&A) expenses, excluding stock-based compensation expense | FY2022 | $250.00M – $265.00M | Lowered |
| Aug 4, 2022 | Total revenue | FY2022 | $155.00M – $165.00M | Raised |
| Aug 4, 2022 | XPOVIO net product revenue | FY2022 | $120.00M – $130.00M | Lowered |
| May 5, 2022 | Non-GAAP R&D and SG&A expenses | FY2022 | $265.00M – $280.00M | Reaffirmed |
| May 5, 2022 | XPOVIO net product revenue | FY2022 | $135.00M – $145.00M | Reaffirmed |
| Feb 8, 2022 | Non-GAAP R&D and SG&A expenses | FY2022 | $265.00M – $280.00M | New |
| Feb 8, 2022 | XPOVIO net product revenue | FY2022 | $135.00M – $145.00M | New |
| Nov 3, 2021 | Non-GAAP R&D and SG&A expenses | FY2021 | $270.00M – $290.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Karyopharm Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- Results
- Update
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Update
- Results
See a number that looks wrong?